Rathi, Nityam
McFarland, Taylor Ryan
Nussenzveig, Roberto
Agarwal, Neeraj
Swami, Umang
Article History
First Online: 28 December 2020
Declarations
:
: No external funding was used in the preparation of this manuscript.
: Neeraj Agarwal has received consultancy fees from Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Janssen, Merck, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics, and institutional research funding from AstraZeneca, Bavarian Nordic, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, GlaxoSmithKline, Immunomedics, Janssen, Medivation, Merck, Nektar, New Link Genetics, Novartis, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon. Roberto Nussenzveig has received advisory fees from Tempus. Nityam Rathi, Taylor Ryan McFarland, and Umang Swami declare that they have no conflicts of interest.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Study conception and design: NR, NA, RN, TRM, and US. Acquisition of data: NR, NA, and US. Analysis and interpretation of data: NR, NA, RN, TRM, and US. Drafting of the manuscript: NR, NA, and US. Critical revision: NR, NA, RN, TRM, and US.